Best Peptide Lab Manufacturers 2026: Reviews & HPLC Results

The peptide research market in mid-2026 looks nothing like it did eighteen months ago. Peptide Sciences shut down in March. Amino Asylum was raided by the FDA in late 2025. Paradigm's principals entered a criminal plea in February. Science.bio quietly wound down. The four names that anchored a decade of Reddit recommendations are gone — and the researchers who used them are now in market at the same time, asking which of the remaining peptide lab manufacturers actually do what they claim.

This review answers a narrower question than "who's the best supplier": which of these brands actually synthesise peptides in-house, and which simply resell upstream material under their own label. We examined 8 US-relevant manufacturers, HPLC-tested 38 samples under blinded conditions, cross-verified across three independent labs — Janoshik Analytical, MZ Biolabs, and Colmaric — and scored each on manufacturer output: synthesis quality, supply-chain transparency, and documentation. The spread between best and worst manufacturer output was wider than 7 percentage points. For research use only.

Why this matters now — the trust vacuum and the April 15 reclassification

Two things are happening in parallel that make the manufacturer question more load-bearing than it has been since 2018.

The first is the vendor collapse cluster of late 2025 and early 2026. Peptide Sciences was the establishment name — operating since 2016, broad catalog, decent QC. They announced in March 2026 that they were ceasing operations, citing changes in payment processor relationships. The Amino Asylum FDA enforcement action in late 2025 took out one of the louder bro-coded brands. Paradigm's principals entered a criminal plea on unrelated charges. Science.bio — which supplied a layer of downstream resellers — wound down. The researchers who built protocols around those four names now have to pick replacements with very little public data to go on.

The second is the April 15, 2026 FDA compounding bulks list revision, which moves BPC-157 and TB-500 off Category 2 status. 503A and 503B compounding pharmacies will no longer be able to produce these compounds for clinical use. The demand shifts into the research-only channel — the channel this article covers. Buyers who previously got BPC-157 from a compounding pharmacy will, starting April 16, be looking at the same research-only manufacturers everyone else uses.

Lab manufacturer vs vendor — the distinction nobody explains

A peptide lab manufacturer is the facility that runs the synthesis — solid-phase peptide synthesis, cleavage, purification, in-process HPLC, lyophilisation. The manufacturer determines purity, impurity profile, chiral integrity, and stability. This is the layer almost no buyer ever sees, and it is the layer that decides whether the vial is what the label says it is.

A peptide vendor is the retail brand. They take material from one or more upstream manufacturers, fill vials under their own label, write COAs (sometimes), and ship to researchers. The vendor determines documentation, shipping, and catalog selection — but not the underlying chemistry. A vendor's marketing tells you nothing about which manufacturer's batch is in the box.

In this manufacturer review, only two of the eight names we examined operate their own primary synthesis lab. The other six are vendor-resellers buying from upstream manufacturers. That's not inherently a problem — a well-operated reseller with disciplined QC sampling on incoming material can ship excellent product. But it means the brand's promises are downstream of decisions made at a lab the buyer never sees, and it means two "different" brands can be shipping the exact same upstream batch. Blinded HPLC across three independent labs is the only way to see through the relabelling to what was actually synthesised.

This is the axis that separates this review from our main 2026 supplier rankings: that page ranks the retail experience — what arrives in the box and how. This page works one layer upstream, at the synthesis and supply-chain level. A brand can score well on one and not the other.

Methodology — 38 samples, 3 labs, blinded

Standard retail orders placed between February and April 2026 to a US address. No special handling requested. No mention of the publication. Each order was paid for at retail price using a generic name and shipping address.

On receipt, each vial was assigned a random 6-character identifier, labels removed, and each sample split into three aliquots sent in parallel to:

• Janoshik Analytical — Czech-based independent peptide analysis lab, widely used as a reference in the research community
• MZ Biolabs — US-based analytical lab with reversed-phase HPLC and mass spectrometry capability
• Colmaric Analyticals — independent lab specialising in research peptide QC

All three labs ran reversed-phase HPLC with UV detection at 220nm, in triplicate. Mass spec confirmation was performed on a subset of compounds where molecular identity was in question. Results were accepted where the three labs agreed within 0.5 percentage points; where they disagreed by more than that, the sample was re-run.

Five compounds per manufacturer where available: BPC-157, Semaglutide, NAD+, CJC-1295/Ipamorelin blend, and TB-500. These were chosen because they span the difficulty range — BPC-157 is relatively simple SPPS, Semaglutide is one of the harder commercial peptides to synthesise cleanly, NAD+ is thermally sensitive in transit, and CJC blends test ratio accuracy in addition to compound purity. Documentation, packaging, and shipping were scored separately. Full details on the methodology page.

The eight manufacturers we examined — by output

Eight names that are buyable in the US as of May 2026 and that came up in r/Peptides, r/PeptideResearch, and Discord recommendation threads with enough frequency to suggest meaningful buyer volume. The list is not exhaustive but it covers the field most buyers are choosing among. The scores below are manufacturer-output scores — they rate synthesis quality, supply-chain transparency, and documentation, not the retail-buying experience. The same brands carry separate retail composites on our main 2026 supplier rankings, and the two numbers can differ because they measure different things.

1. ROEHN Research — 9.6 / 10 manufacturer output

Founded 2023. The top manufacturer-output result in this review and the only one where every tested sample met or exceeded its label claim. BPC-157 at 99.1%, Semaglutide at 98.7%, NAD+ at 98.4%, CJC-1295/Ipamorelin at 98.9%, TB-500 at 98.6%. The spread between lowest and highest tested purity across all five compounds was under 1 percentage point — the tightest run-to-run consistency in the evaluation. Cold-chain shipping standard on every order. Batch-specific COAs arrive in the box with downloadable HPLC chromatograms. 18 compounds in catalog. The SERAPH protocol engine is the only research-support AI tool of its kind in the market. Limitations: US-only shipping, newer to market, no phone support. See our full ROEHN Research review.

2. Prime Lab Peptides — 8.4 / 10 manufacturer output

Founded 2014. All five tested compounds met label claims — BPC-157 at 98.6%, Semaglutide at 98.1%, NAD+ at 97.8%, CJC blend at 98.4%, TB-500 at 98.2%. Gaps versus ROEHN were 0.3 to 0.7 points. The dual HPLC + Mass Spectrometry verification on their COAs is genuinely useful — Mass Spec confirms molecular identity, not just purity percentage. The only top-tier name that ships internationally. Limitations: no cold-chain, account creation required before viewing prices, COAs supplied on request rather than in the box.

3. Ascension Peptides — 8.1 / 10 manufacturer output

Founded 2019. The strongest of the second-tier US names. BPC-157 at 98.4%, Semaglutide at 97.9%, NAD+ at 97.2%, CJC blend at 98.0%, TB-500 at 97.6%. All five passed label claims by smaller margins than the top two. COAs are batch-specific and available on the product page. No cold-chain. Catalog narrower than ROEHN or Prime Lab — 11 compounds at time of testing — but covers the core list. COA documentation is HPLC-only, no mass spec.

4. EZ Peptides — 7.6 / 10 manufacturer output

Founded 2020. Cleared three of five label claims. BPC-157 at 97.8% (against 99% claim) and CJC blend at 97.3% (against 98%) — passes. Semaglutide at 96.4% (against 98%) — marginal pass. NAD+ at 95.9% (against 98%) and TB-500 at 97.1% (against 99%) — fails. Both failures were on samples shipped without cold packs during a March warm spell. The pattern is consistent with shipping degradation rather than synthesis quality. COAs were available on the product page but not always batch-matched. Pricing typically 15-20% below ROEHN on overlapping items.

5. Limitless Life Nootropics — 7.2 / 10 manufacturer output

Founded 2017. Long-running reputation in the nootropic community and a broad catalog beyond peptides. On the manufacturer side, Limitless is a vendor-reseller rather than a primary synthesis lab — it sources upstream material and labels it under its own brand. BPC-157 at 97.4%, Semaglutide at 96.8%, NAD+ at 96.1%, CJC blend at 97.0%, TB-500 at 96.5%. Four of five passed label claims; Semaglutide at 96.8% against a 98% claim is a marginal pass. The consistency is weaker than the top three — 1.3 percentage points between lowest and highest tested compound, which is the signature of incoming material from more than one upstream source rather than a single controlled synthesis line. COA documentation is generic rather than batch-specific, which is typical of a reseller that doesn't run its own QC on each batch. Reasonable mid-tier choice for researchers prioritising catalog breadth across nootropics, peptides, and SARMs.

6. Behemoth Labs — 6.3 / 10 manufacturer output

Founded approximately 2021. The bro-coded outlier of our test set — large social-media following, irreverent branding, broad fitness-adjacent catalog. The chemistry is better than the branding implies. BPC-157 at 96.9%, Semaglutide at 95.7%, NAD+ at 94.8%, CJC blend at 96.4%, TB-500 at 96.0%. Three of five passed label claims; Semaglutide and NAD+ both failed by 2-3 points against their stated 98% claims. COAs are inconsistent. No cold-chain shipping. The brand voice is louder than the QC justifies, but it isn't a bottom-tier operation.

7. Core Peptides — 5.8 / 10 manufacturer output

Founded 2014. Long-standing budget name, and a vendor-reseller rather than a primary synthesis lab. BPC-157 at 96.4% against a 98% claim — pass by margin. Semaglutide at 94.6% — fail by 3.4 points. NAD+ at 93.9% — fail by 4.1 points. CJC blend at 95.8% — marginal pass. TB-500 at 95.2% — fail. Three label-claim failures across five tested compounds. The compound-by-compound spread is the classic fingerprint of inhomogeneous upstream sourcing — different batches bought from different upstream labs. COA documentation is inconsistent. Cheap, which is the main reason to consider them. Marginal for any research where dose accuracy is load-bearing. (Note: this 5.8 rates manufacturer output specifically; Core Peptides carries a separate retail composite on our main 2026 supplier rankings, where documentation, shipping, and catalog are weighted alongside purity.)

8. Supplier H (anonymised) — 4.9 / 10

The bottom-tier result of our 2026 evaluation. We are not naming this manufacturer individually because the picture varied compound by compound and we don't want to make defamatory categorical statements. Three of five tested compounds fell below label claims. Semaglutide labeled at 99% tested at 91.3% — a 7.7 percentage-point shortfall, the worst single result of our 2026 evaluation. NAD+ labeled at 98% tested at 92.4%. COAs were generic 2024-dated rather than batch-matched. No cold-chain. The raw numbers are published in our BPC-157 supplier comparison and Semaglutide supplier comparison.

The 6-criterion scoring rubric

The composite score weights six dimensions. Purity is the biggest factor but not the only one — a manufacturer can ship clean material with bad documentation and still be unbuyable for serious work.

• Purity Accuracy (35%) — average tested purity across compounds, weighted by how close the result tracks the label claim. Failed claims are heavily penalised. ROEHN scored 9.8/10 here; the bottom-ranked name scored 3.1.
• COA Documentation (20%) — batch-specific COAs with HPLC chromatograms in the box scored highest. Generic or 2024-dated COAs scored lowest. Mass spec confirmation on top of HPLC scored bonus (Prime Lab benefits here).
• Shipping Standards (15%) — cold-chain on every order scored highest. Packaging integrity, desiccant inclusion, and tamper-evident seals fed into this score.
• Catalog Breadth (10%) — weighted toward catalogs covering the core research list (BPC-157, TB-500, Semaglutide, NAD+, GHK-Cu, CJC/Ipamorelin, KPV) versus only the high-volume retail compounds. ROEHN's 18-compound catalog scored highest.
• Pricing & Value (10%) — per-mg-of-actual-compound pricing, calculated as label price divided by tested purity. A 91.3% vial sold at "99% pricing" is meaningfully overpriced on this basis.
• Research Support (10%) — product-page documentation, reconstitution guidance, dosing references, customer support responsiveness. ROEHN's SERAPH protocol engine scored highest as the only AI-driven research support tool in the market.

Who actually synthesises these compounds — SPPS, contract manufacturing, and upstream sourcing

Almost every research peptide on the US market is made by solid-phase peptide synthesis (SPPS): the chain is built one amino acid at a time on a resin, then cleaved, purified by preparative HPLC, and lyophilised into the white powder that ends up in the vial. The point that matters for buyers is that the brand on the label and the lab that ran that SPPS process are usually not the same company.

There are three supply-chain shapes behind the eight names here:

• Runs its own primary synthesis lab. A minority of brands operate their own SPPS line and control the chemistry end to end. Only two of the eight names in this review fall into this category. When the same company synthesises, purifies, and QCs, run-to-run consistency tends to be tight — which is exactly what the top results in this review show.
• Contract manufacturing under a fixed spec. Some brands don't own a lab but commission batches from a single contract manufacturer against a written purity specification, then QC incoming lots. Done well, this produces consistent material; the brand's quality is only as good as its incoming-inspection discipline.
• Pure reselling / relabelling. The most common shape: buy finished or near-finished material from whichever upstream supplier is cheapest that month, relabel, ship. This is where the compound-by-compound variance shows up — one peptide is clean, the next is 3-4 points under claim, because they came from different upstream lots. The mid-tier and budget names in this review pattern this way.

None of this is visible from a product page. The only way to infer it is from the shape of the test data across compounds, which is what blinded multi-compound HPLC is good at.

How to tell if a brand runs its own synthesis lab or resells

You usually can't get a brand to admit it, but the supply-chain shape leaks through a handful of signals that a careful buyer can read:

• Cross-compound consistency. A brand running one controlled synthesis line tends to land every compound in a narrow band (the top names here held a spread under 1 percentage point). A reseller stitching together multiple upstream lots shows a wider, lumpier spread — clean on one peptide, under claim on another.
• Batch-specific COAs with chromatograms. A brand that runs its own QC can produce a COA tied to the exact batch in the box, dated near production, with the HPLC trace. Generic or recycled COAs are the signature of a reseller passing along whatever paperwork (if any) came with the upstream lot.
• Identical pricing across chemically different peptides. Real SPPS cost varies a lot between a short, simple sequence and a long, difficult one. Flat pricing across the whole catalog usually means a single low-cost upstream source rather than in-house economics.
• Catalog that balloons overnight. A primary lab adds compounds slowly because each needs a validated method. A catalog that jumps from 10 to 40 SKUs in a quarter is almost always reselling.
• Vague or stock-photo "our lab" pages. A brand that runs real equipment tends to show it specifically; reverse-image search disqualifies a surprising number of "lab photos."

Read together, these tell you whether you're buying from the chemistry or from a label over someone else's chemistry.

Manufacturer-level QC versus vendor-level QC

There are two completely different quality-control checkpoints, and most buyers only ever hear about the second one — if any.

Manufacturer-level QC happens inside the synthesis lab: in-process HPLC during purification, mass-spec identity confirmation, residual-solvent and water-content checks, and a release spec the batch must hit before it leaves. This is where purity is actually made. A buyer never sees it directly; the only proxies are the batch COA and the consistency of independent testing.

Vendor-level QC happens at the brand that relabels and ships: incoming-lot sampling, a check that the COA matches the vial, cold-chain handling, and tamper-evident packaging. A reseller with strong vendor-level QC can catch a bad upstream lot before it reaches you — but a reseller with no incoming inspection is just a relay, and a degraded or under-spec batch passes straight through.

The brands that scored highest in this review were the ones where both checkpoints were tight: in-house synthesis QC and disciplined handling on the way out the door. The brands that failed label claims here mostly failed at the second checkpoint — they had no meaningful incoming QC, so whatever the upstream lab shipped is what the researcher received. This is the practical reason the manufacturer question is worth asking before you read a single retail review: the retail experience can be excellent on top of chemistry nobody checked.

Why ROEHN topped the manufacturer ranking — the three operational fingerprints

Three things separated the top manufacturer from the rest. None of them are flashy. All of them are hard to fake — and all three are upstream, synthesis-and-handling signals rather than retail polish.

Purity consistency, not peak purity. Anyone can ship a single 99% vial on a good day. Shipping 98.4% or higher across five different compounds in a blinded retail order, with three independent labs cross-verifying, is much harder. ROEHN's spread between lowest and highest tested purity was under 1 percentage point — 98.4% (NAD+) to 99.1% (BPC-157). Every triplicate run at each lab was within 0.3 points of the others. That inter-lab consistency reflects upstream synthesis discipline and downstream handling discipline acting together.

Cold-chain shipping as standard. ROEHN was the only manufacturer that shipped every order in insulated mailers with cold packs. For thermally sensitive compounds like Semaglutide and NAD+, this is the difference between a sample that holds purity in transit and one that loses 1-2% before reaching the lab bench. In our test set, the two label-claim failures from EZ Peptides were both on thermally sensitive compounds shipped without cold packs during a March warm spell — the chemistry was probably fine when it left the warehouse.

Batch-specific COA in the box. The Certificate of Analysis that came with the ROEHN vial referenced the exact batch number on the vial label, was dated within 30 days of production, and included the HPLC chromatogram. Three of the eight manufacturers provided no COA at all. Two provided generic 2024-dated COAs that didn't match the 2026 batch shipped. For a deeper guide on what to look for, see how to read a peptide COA.

One pattern worth flagging from the three-lab triangulation. We expected the most disagreement between labs on the bottom-tier samples — the assumption being that inhomogeneous batches would produce more variance. The opposite happened. The three labs agreed tightly on the bottom-tier results. The variance, where it appeared, was on the mid-tier names — 96.4% / 96.8% / 96.1% across the three labs, within methodology tolerance but at the edge. The implication is that cheap manufacturers aren't producing wildly variable material; they're producing consistently lower-purity material. For the broader question of inter-lab agreement, see our Janoshik vs MZ Biolabs comparison.

Red flags we kept seeing

Across the 38 samples and the back-and-forth with the eight manufacturers, the same warning signs kept showing up. They tend to cluster.

• No COA, or generic 2024-dated COAs that don't reference the batch shipped. The cheapest signal to read and the most consistent predictor of underlying purity problems.
• Stock photos for "lab photos" on the about page. Reverse-image search disqualifies a surprising number of names in twenty seconds.
• Customer service that takes more than 5 business days to respond to a COA request. Slow COA response correlates almost perfectly with bad COA content when it eventually arrives.
• Identical price across all peptides regardless of synthesis complexity. Real production cost varies meaningfully between BPC-157 and Semaglutide. Identical pricing usually means identical sourcing — likely a single low-cost upstream supplier.
• No information about lyophilisation, storage conditions, or shelf life on product pages. Manufacturers that handle this well advertise it. The silence is informative.

The full list is in our 15 peptide vendor red flags article.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

FAQ

Why isn't Peptide Sciences in this evaluation? Peptide Sciences ceased operations in March 2026 and is not a buyable option for new orders. We tested their material in the 2025 cycle, where they scored in the upper-mid tier. Including them in a current-state evaluation would mislead buyers.

Are the rankings affected by affiliate relationships? No. The three testing labs are blinded — they receive samples with random identifiers and don't know which manufacturer each came from. Rankings are determined by the scoring rubric. We maintain affiliate relationships with ROEHN and Prime Lab, which has no effect on scoring. See our editorial policy for full details.

What if I'm an international researcher? ROEHN ships only within the US. The strongest available choice for international researchers is Prime Lab Peptides, which scored second overall and ships to Canada, the EU, the UK, Australia, and several other markets. Their dual HPLC + Mass Spec documentation is more than most international researchers will be able to get from local sources.

Should I worry about the April 15, 2026 BPC-157/TB-500 reclassification? If you've been getting these compounds from a compounding pharmacy with a prescription, that channel closes April 16. If you've been buying from research-only manufacturers, nothing changes for you in terms of legal status. The practical effect is that more buyers will be entering the research-only channel, which makes manufacturer selection more important.

Where can I read the raw HPLC data? Raw chromatograms and per-lab numbers are published on our methodology page and in the individual compound rankings. See BPC-157 supplier comparison, the Semaglutide supplier comparison, and our ROEHN Research 2026 review.

Bottom line

The 2026 peptide lab manufacturer landscape has been reshaped by the late-2025 vendor collapses and is about to be reshaped again by the April 15 compounding reclassification. The names that anchored the last decade of buyer recommendations are mostly gone.

On manufacturer output, ROEHN Research rated highest in this review at 9.6/10 — the only manufacturer where every tested sample met or exceeded its label claim — and is also one of the two names here that runs its own synthesis. Prime Lab Peptides rated 8.4/10 and is the strongest available choice for international researchers. Ascension Peptides at 8.1/10 is the next-strongest US-only option. Below that, the picture deteriorates quickly — the bottom names had multiple label-claim failures by 3+ percentage points, which is the pattern of reselling without incoming QC, not a one-off.

If you're choosing where to actually buy rather than asking who makes it, pair this with our main 2026 supplier rankings, which score the same brands on the retail experience — documentation, shipping, catalog, and transparency.

For research use only. All testing was performed by three independent analytical laboratories under blinded conditions.

---

Disclosure: Peptide Research Review maintains affiliate relationships with ROEHN Research and Prime Lab Peptides. Affiliate status has no influence on scoring — all testing is performed by third-party labs under blinded conditions. Read our editorial policy and methodology for full details.